laser acupunture,laser therapy,smoking addiction

1. Press Release
Theralase Effective in the Treatment of Tobacco Addiction
Toronto, Ontario – October 12, 2012 -- Theralase Technologies Inc. (TSX-V: TLT) announced today that
the Theralase therapeutic laser system, has been proven clinically effective in the treatment of tobacco
addiction.
The Theralase technology was clinically evaluated on over 500 subjects, who were heavy smokers, to
validate if they were able to reduce their smoking by at least 25%, 30 days after receiving the Theralase
laser treatment. The results of the clinical study demonstrated that 405 (73.8%) subjects had reduced
their consumption of tobacco products by 25% or more, with 373 (92.0%) completely eliminating use
and 32 of those subjects (8.0%) showing a reduction of at least 25%.
Smoking is one of the most preventable illnesses that plague the American population. In 2009, the
Centers for Disease Control and Prevention estimated that smoking accounted for $96 billion a year in
direct health care costs and an additional $97 billion a year in lost productivity. Smoking addiction is a
complex condition, which can disrupt a person’s life, leading to severe health concerns, deterioration
of major organs, incurable diseases and eventually pre-mature death. In fact, more deaths are caused
each year by tobacco use than by all deaths from human immunodeficiency virus (HIV), illegal drug use,
alcohol use, motor vehicle injuries, suicides and murders combined, with cigarette smoking causing 1
out of every 5 deaths in the United States each year.
Roger Dumoulin-White, President and CEO of Theralase stated that “Due to the complexity of smoking
addiction and the poor success rate that alternative cessation methods have had, this independent
clinical study was commissioned to enroll 549 subjects, from a homogeneous, cosmopolitan population
of heavy smokers. The treatment group consisted of a relatively equal representation of male and
female subjects with an average age in the mid to late forties. A Theralase therapeutic laser system
was applied to specific ear and body acupuncture points to determine if the subject could reduce their
smoking consumption by 25% or more 30 days after treatment. The results of the clinical study
demonstrated that at the 30 day follow-up end point, 405 (73.8%) subjects had met the outcome
criteria and had reduced their consumption of tobacco products by 25% or more, with 373 of those
subjects (92.0%) completely eliminating use of tobacco products and 32 of those subjects (8.0%)
showing a reduction of at least 25%. This non-pharmacologic and non-invasive therapeutic modality
exceeds the effectiveness of other therapeutic options currently available for smoking cessation
treatment, including nicotine patch, nicotine gum and other pharmaceutical alternatives.”
Dr. Arkady Mandel, Chief Scientific Officer of Theralase said, “Due to the significant reduction in the
consumption of tobacco products by 405 (73.8%) subjects by 25% or more at the 30 day follow-up end
point, the Theralase laser technology may find itself as a first line approach to combatting long term
tobacco addiction in the not too distant future. Theralase laser acupuncture treatments may represent
a safe and effective alternative for reducing the amount of tobacco products consumed by smokers”.
About Theralase Technologies Inc.:

2. Press Release
Theralase Technologies Inc., founded in 1995, designs, develops, manufactures and markets patented,
superpulsed laser technology utilized in biostimulation and biodestruction applications. Theralase
technology is safe and effective in treating pain, inflammation and for tissue regeneration of neural
muscular skeletal conditions and wound healing in both humans and animals. Theralase complies with
all FDA, Health Canada, CE and international regulatory approvals to produce clinically effective, safe
and high quality products. Theralase also develops patented Photo Dynamic Compound (PDC)
technology focused at targeting and destroying cancers, bacteria and viruses when light activated by
Theralase’s proprietary and patented laser technologies.
For further information please visit www.theralase.com, regulatory filings may be viewed by visiting
www.sedar.com.
This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking
statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to
update these forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts
responsibility for the adequacy or accuracy of this release.
For More Information, please contact:
Roger Dumoulin - White,
President and CEO
416-447-8455 ext. 225
rwhite@theralase.com
Kristina Hachey
Chief Financial Officer
416-447-8455 ext. 224
khachey@theralase.com
Greg Bewsh
Director of Investor Relations
416-447-8455 ext. 262
gbewsh@theralase.com
Arkady Mandel
Chief Scientific Officer
416-447-8455 ext. 242
amandel@theralase.com